Based in Hyderabad, India, Bharat Biotech is expanding its vaccine portfolio with a focus on antimicrobial resistance (AMR), a growing global health challenge. The company, known internationally for developing Covaxin during the Covid-19 pandemic, is now working on vaccines designed to prevent hospital-acquired infections, particularly in patients undergoing surgeries. According...
Germany Approves Bharat Biotech’s COVAXIN for Travel
German Ambassador to India and Bhutan, Walter J Lindner, announced that the government of Germany recognized WHO-listed Bharat Biotech's Covid vaccine, COVAXIN, for travel to the country starting June 1. In November last year the World Health Organization issued an emergency use listing for Covaxin, adding to a growing portfolio...
India Administers 1 Billion Doses of the Covid-19 Vaccine
India has crossed the landmark of vaccinating 1 billion individuals in about nine months since the drive began. The countrywide vaccination program was launched on January 16 with the aim of covering all of India’s 944 million adults this year. As of now, 75% of them have got at least...
India’s Own Covid-19 Vaccine is 81 Percent Effective
Yesterday, Hyderabad-based Bharat Biotech published interim results from the Phase 3 trial of it Covid-19 vaccine, branded as Covaxin. 25,8000 subjects participated in the trial. The trial found 43 cases of COVID-19 patients who showed symptoms ranging from mild to moderate and severe, and of the total cases, 36 were from...
Ocugen licenses India’s Covid-19 Vaccine for U.S use
Pennsylvania-based Ocugen just signed an agreement giving in the rights to the Bharat Biotech Covid-19 vaccine candidate, Covaxin, in the United States. Ocugen will be responsible for clinical development, regulatory approval (including Emergency Use Authorization) and commercialization of this Indian vaccine in America. Covaxin is an advanced stage whole-virion inactivated...